Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, including DLBCL and related …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Lymphoma
• B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Ebv-positive Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3b
• High-grade B-cell Lymphoma
• Indolent B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Breyanzi (lisocabtagene maraleucel)
• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: Patrick C. Johnson, MD | Conditions: Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-29